Wire · opportunities
Clinical trial combines CRISPR gene editing with stem cell transplants to treat aggressive ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 August 2026 · Fusion42 review
A clinical trial used CRISPR to delete CD33 from donor stem cells for patients with aggressive blood cancers, allowing safer use of CD33-targeted therapies post-transplant. The trial showed edited cells rebuilt blood production normally and some patients tolerated maintenance therapy without severe blood cell suppression, potentially improving treatment safety for AML and MDS.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your biotech or digital health startup can now explore safer immune therapies by targeting leukemia without harming healthy blood cells. This opens a new pathway to combine gene editing with transplantation to reduce toxicity and improve patient outcomes.
◆ Coverage
1 source · 2 Aug 2026
◆ Related on Wire
◆ Topics